## Hemamali Samaratunga Mbbs, Frcpa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/380965/publications.pdf

Version: 2024-02-01

		53794	33894
217	10,971	45	99
papers	citations	h-index	g-index
221	221	221	10706
221	221	221	10706
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature Medicine, 2022, 28, 154-163.	30.7	143
2	Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. Prostate, 2022, 82, 576-583.	2.3	3
3	Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3289-3294.	6.4	18
4	Detection of perineural invasion in prostate needle biopsies with deep neural networks. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 73-82.	2.8	7
5	Prognostic significance of percentage Gleason grade 5 prostatic adenocarcinoma in needle biopsies from patients treated by radical prostatectomy. Pathology, 2022, 54, 694-699.	0.6	1
6	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. Head and Neck Pathology, 2021, 15, 628-637.	2.6	1
7	Tumour-like lesions of the urinary bladder. Pathology, 2021, 53, 44-55.	0.6	11
8	Benign mimics of prostate cancer. Pathology, 2021, 53, 26-35.	0.6	7
9	Recent advances in urological pathology. Pathology, 2021, 53, 1-2.	0.6	0
10	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	2.5	4
11	Histological findings of totally embedded robot assisted laparoscopic radical prostatectomy (RALP) specimens in 1197 men with a negative (low risk) preoperative multiparametric magnetic resonance imaging (mpMRI) prostate lobe and clinical implications. Prostate Cancer and Prostatic Diseases, 2021, 24, 398-405.	3.9	2
12	Staging of renal cell carcinoma: current progress and potential advances. Pathology, 2021, 53, 120-128.	0.6	18
13	Intraductal carcinoma of the prostate is not a diagnostic entity. Histopathology, 2021, 78, 342-344.	2.9	6
14	Prognostic significance of morphological patterns of Gleason grade 5 prostatic adenocarcinoma diagnosed on needle biopsy. Pathology, 2021, 53, 199-204.	0.6	3
15	Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1109-1116.	2.8	7
16	Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. Eur Urol 2021;79:225–31. European Urology, 2021, 79, e141-e142.	1.9	2
17	ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. American Journal of Surgical Pathology, 2021, 45, 1118-1126.	3.7	36
18	Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. Annals of Diagnostic Pathology, 2021, 52, 151733.	1.3	9

#	Article	IF	CITATIONS
19	Intraductal Carcinoma of the Prostate. American Journal of Surgical Pathology, 2021, Publish Ahead of Print, 1527-1533.	3.7	6
20	Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies—Current Status and Next Steps. European Urology Focus, 2021, 7, 687-691.	3.1	18
21	The emerging role of artificial intelligence in the reporting of prostate pathology. Pathology, 2021, 53, 565-567.	0.6	0
22	External Validation and Addition of Prostate-specific Membrane Antigen Positron Emission Tomography to the Most Frequently Used Nomograms for the Prediction of Pelvic Lymph-node Metastases: an International Multicenter Study. European Urology, 2021, 80, 234-242.	1.9	35
23	Lichen sclerosus presenting as an isolated bulbar urethral stricture. Urology Case Reports, 2021, 39, 101794.	0.3	0
24	Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey. Journal of Clinical Pathology, 2021, 74, 291-299.	2.0	14
25	Dataset for the reporting of urinary tract carcinoma—biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). Modern Pathology, 2020, 33, 700-712.	5.5	16
26	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232.	10.7	364
27	Dataset for the reporting of carcinoma of the bladder—cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin. 2020. 476. 521-534.	2.8	11
28	Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology, 2020, 52, 192-196.	0.6	29
29	The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2020, 44, e87-e99.	3.7	292
30	The utility of artificial intelligence in the assessment of prostate pathology. Histopathology, 2020, 76, 790-792.	2.9	9
31	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 777-786.	2.8	20
32	Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 2020, 52, 507-514.	0.6	20
33	Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy. BJU International, 2020, 126, 6-11.	2.5	12
34	Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology, 2020, 77, 284-292.	2.9	19
35	Assessment of tumourâ€associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology, 2019, 74, 284-290.	2.9	24
36	PD â€L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate. Apmis, 2019, 127, 554-560.	2.0	11

#	Article	IF	CITATIONS
37	Sponsor Acknowledgements. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 10-12.	1.1	о
38	Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis. Translational Andrology and Urology, 2019, 8, S147-S155.	1.4	19
39	Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Translational Andrology and Urology, 2019, 8, S123-S137.	1.4	11
40	Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation. Pathology, 2019, 51, 463-473.	0.6	47
41	Emerging entities of renal cell neoplasia. Surgical and Experimental Pathology, 2019, 2, .	0.6	5
42	Risk of metastatic disease on <sup>68</sup> galliumâ€prostateâ€specific membrane antigen <scp>positron emission tomography</scp> / <scp>computed tomography</scp> scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU International, 2019, 124, 401-407.	2.5	80
43	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2019, 75, 453-467.	2.9	3
44	Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma. Pathology, 2019, 51, 349-352.	0.6	3
45	Intraductal carcinoma of the prostate: a critical re-appraisal. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 525-534.	2.8	40
46	Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate, 2019, 79, 920-928.	2.3	9
47	The International Society of Urological Pathology Education web—a web-based system for training and testing of pathologists. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 577-584.	2.8	11
48	Evolution, controversies and the future of prostate cancer grading. Pathology International, 2019, 69, 55-66.	1.3	6
49	Disruption of Spermatogenesis and Infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2). Cerebellum, 2019, 18, 448-456.	2.5	19
50	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter—Nephroureterectomy and Ureterectomy Specimens. American Journal of Surgical Pathology, 2019, 43, e1-e12.	3.7	5
51	Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?. American Journal of Surgical Pathology, 2019, 43, 1249-1252.	3.7	8
52	Grading of renal cell carcinoma. Histopathology, 2019, 74, 4-17.	2.9	188
53	Datasets for the reporting of neoplasia of the testis: recommendations from the International Collaboration on Cancer Reporting. Histopathology, 2019, 74, 171-183.	2.9	13
54	MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature. World Journal of Urology, 2019, 37, 1263-1279.	2.2	25

#	Article	IF	CITATIONS
55	Utility of Pathology Imagebase for standardisation of prostate cancer grading. Histopathology, 2018, 73, 8-18.	2.9	36
56	Fuhrman grading is inappropriate for papillary renal cell carcinoma. World Journal of Urology, 2018, 36, 1335-1336.	2.2	3
57	A novel technique for biobanking of large sections of radical prostatectomy specimens. Histopathology, 2018, 72, 481-489.	2.9	2
58	Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations. Pathology, 2018, 50, 60-73.	0.6	29
59	Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World Journal of Urology, 2018, 36, 15-20.	2.2	20
60	Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nature Communications, 2018, 9, 4915.	12.8	135
61	Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?. Pathology, 2018, 50, 504-510.	0.6	10
62	Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncology, The, 2018, 19, 1051-1060.	10.7	304
63	Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk Prediction. ACS Nano, 2018, 12, 8362-8371.	14.6	66
64	Re: Comment on Egevad <i>et al</i> ., †Utility of Pathology Imagebase for standardisation of prostate cancer grading'. Histopathology, 2018, 73, 361-362.	2.9	0
65	The current status of renal cell carcinoma and prostate carcinoma grading. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 1057-1062.	1.5	1
66	Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000–2012. BJU International, 2017, 119, 50-56.	2.5	32
67	Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System. Archives of Pathology and Laboratory Medicine, 2017, 141, 182-183.	2.5	4
68	<scp>UICC</scp> drops the ball in the 8th edition <scp>TNM</scp> staging of urological cancers. Histopathology, 2017, 71, 5-11.	2.9	37
69	Editorial Comment to Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. International Journal of Urology, 2017, 24, 286-287.	1.0	0
70	Kallikreinâ€related peptidase 4 induces cancerâ€associated fibroblast features in prostateâ€derived stromal cells. Molecular Oncology, 2017, 11, 1307-1329.	4.6	17
71	Genetic profile of ductal adenocarcinoma of the prostate. Human Pathology, 2017, 69, 1-7.	2.0	20
72	MP53-10 ROBOT-ASSISTED SALVAGE NODE DISSECTION FOR OLIGOMETASTATIC NODAL DISEASE DETECTED BY 68GALLIUM-PSMA PET/CT: A MULTICENTRE RETROSPECTIVE SERIES. Journal of Urology, 2017, 197, .	0.4	0

#	Article	IF	CITATIONS
73	Initial multicentre experience of <sup>68</sup> galliumâ€PSMA PET/CT guided robotâ€assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU International, 2017, 120, 673-681.	2.5	67
74	Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology, 2017, 71, 641-647.	2.9	19
75	The decline of medical publishing: the rise of the pseudo-journal. Pathology, 2017, 49, 673-674.	0.6	0
76	Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study. Pathology, 2017, 49, 715-720.	0.6	14
77	Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology, 2017, 71, 918-925.	2.9	98
78	Pathology Imagebase—a reference image database for standardization of pathology. Histopathology, 2017, 71, 677-685.	2.9	19
79	Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1. European Urology, 2017, 71, e52-e53.	1.9	0
80	Longâ€ŧerm outcomes of highâ€doseâ€rate brachytherapy for intermediate―and highâ€risk prostate cancer with a median followâ€up of 10 years. BJU International, 2017, 120, 56-60.	2.5	29
81	The evolution of Gleason grading of prostate cancer. Journal of Diagnostic Pathology, 2017, 12, 5.	0.0	3
82	One is the new six: The International Society of Urological Pathology (ISUP) patient-focused approach to Gleason grading. Canadian Urological Association Journal, 2016, 10, 339.	0.6	14
83	Pleomorphic giant cell carcinoma of the urinary bladder: an extreme form of tumour deâ€differentiation. Histopathology, 2016, 68, 533-540.	2.9	35
84	Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol. Contemporary Clinical Trials, 2016, 50, 16-20.	1.8	5
85	International Society of Urological Pathology ( <scp>ISUP</scp> ) grading of prostate cancer – An <scp>ISUP</scp> consensus on contemporary grading. Apmis, 2016, 124, 433-435.	2.0	152
86	A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma. Journal of Clinical Pathology, 2016, 69, 661-671.	2.0	49
87	In Regard to Zietman et al. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1126-1127.	0.8	3
88	Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochemical and Biophysical Research Communications, 2016, 473, 47-53.	2.1	6
89	MP03-12 STAGING ADVANCED AND METASTATIC CLEAR CELL RENAL CELL CARCINOMA WITH 68 GALLIUM PSMA PET FOR TREATMENT PLANNING. Journal of Urology, 2016, 195, .	0.4	2
90	Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers. Prostate International, 2016, 4, 97-102.	2.3	9

#	Article	IF	CITATIONS
91	New Gleason grading system: Statement from the editors of 6 journals. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 479-480.	1.6	0
92	Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of nonâ€prostatic origin: a comparative study. Apmis, 2016, 124, 263-270.	2.0	28
93	Prostate cancer grading: recent developments and future directions. BJU International, 2016, 117, 7-8.	2.5	19
94	Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 68, 475-481.	2.9	48
95	Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology, 2016, 48, 613-616.	0.6	27
96	Consensus guidelines for reporting prostate cancer Gleason Grade. BJU International, 2016, 118, E1-2.	2.5	10
97	Reply by the Authors. Urology, 2016, 96, 179-180.	1.0	0
98	Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet, The, 2016, 388, 1057-1066.	13.7	539
99	Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Journal of Urology, 2016, 196, 1321-1323.	0.4	0
100	From Gleason to International Society of Urological Pathology (ISUP) grading of prostate cancer. Scandinavian Journal of Urology, 2016, 50, 325-329.	1.0	31
101	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology, 2016, 69, 441-449.	2.9	82
102	Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology, 2016, 48, 398-405.	0.6	42
103	International Society of Urological Pathology (ISUP) Grading of Prostate Cancer. American Journal of Surgical Pathology, 2016, 40, 858-861.	3.7	37
104	Reply: Gleason and Fuhrman no longer make the grade. Histopathology, 2016, 69, 341-342.	2.9	0
105	Utility of Reporting the Percentage of High-grade Prostate Cancer. European Urology, 2016, 69, 599-600.	1.9	14
106	Histologic prognostic markers for renal cell neoplasia. Diagnostic Histopathology, 2016, 22, 65-72.	0.4	1
107	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Targeted Oncology, 2016, 11, 345-351.	3.6	56
108	Multifocal Primary Neoplasms in Kidney Allografts: Evaluation of Two Cases. Journal of Kidney Cancer and VHL, 2016, 3, 14-22.	1.0	1

#	Article	IF	CITATIONS
109	The prognostic significance of the 2014 International Society of Urological Pathology (ISUP) grading system for prostate cancer. Pathology, 2015, 47, 515-519.	0.6	48
110	Cancer stem cell markers in prostate cancer: an immunohistochemical study of ALDH1, SOX2 and EZH2. Pathology, 2015, 47, 622-628.	0.6	38
111	Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final <scp>G</scp> leason score and clinical risk category? A comparative analysis. BJU International, 2015, 116, 26-30.	2.5	36
112	Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Prostate, 2015, 75, 539-549.	2.3	37
113	Mesenchymal tumors of adult kidney. Seminars in Diagnostic Pathology, 2015, 32, 160-171.	1.5	14
114	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
115	Active surveillance for prostate cancer: the role of the pathologist. Pathology, 2015, 47, 1-3.	0.6	8
116	The ISUP system of staging, grading and classification of renal cell neoplasia. Journal of Kidney Cancer and VHL, 2014, 1, 26-39.	1.0	41
117	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 623-628.	2.8	41
118	The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the	2.5	117
119	Prostate Cancer Foundation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1387-1405. Total submission of pelvic lymphadenectomy tissues removed during radical prostatectomy for prostate cancer increases lymph node yield and detection of micrometastases. Histopathology, 2014, 64, 399-404.	2.9	31
120	Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology, 2014, 65, 216-227.	2.9	40
121	Percutaneous renal tumour biopsy. Histopathology, 2014, 65, 295-308.	2.9	19
122	Optimising pre-analytical factors affecting quality of prostate biopsies: the case for site specific labelling and single core submission. Pathology, 2014, 46, 579-580.	0.6	3
123	Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men. Pathology, 2014, 46, 11-14.	0.6	8
124	Effective maybe, but is it costâ€effective? A reply. Histopathology, 2014, 65, 729-730.	2.9	2
125	Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?. Journal of Clinical Pathology, 2014, 67, 97-104.	2.0	78
126	Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 559-565.	2.8	26

#	Article	IF	CITATIONS
127	Wave propagation analysis in laminated composite plates with transverse cracks using the wavelet spectral finite element method. Finite Elements in Analysis and Design, 2014, 89, 19-32.	3.2	34
128	A Progress Report on a Prospective Randomised Trial of Open and Robotic Prostatectomy. European Urology, 2014, 65, 512-515.	1.9	15
129	Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder. Anticancer Research, 2014, 34, 6779-84.	1.1	6
130	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology, 2013, 37, 1469-1489.	3.7	922
131	Premalignant lesions of the urinary bladder. Pathology, 2013, 45, 243-250.	0.6	18
132	Handling and Staging of Renal Cell Carcinoma. American Journal of Surgical Pathology, 2013, 37, 1505-1517.	3.7	118
133	Recently described and unusual variants of urothelial carcinoma of the urinary bladder. Pathology, 2012, 44, 407-418.	0.6	43
134	Evidence for Steroidogenic Potential in Human Prostate Cell Lines and Tissues. American Journal of Pathology, 2012, 181, 1078-1087.	3.8	29
135	Gleason grading: past, present and future. Histopathology, 2012, 60, 75-86.	2.9	85
136	Genetic Association of the KLK4 Locus with Risk of Prostate Cancer. PLoS ONE, 2012, 7, e44520.	2.5	18
137	Alpha-fetoprotein-producing carcinoma of the renal pelvis exhibiting hepatoid and urothelial differentiation. Anticancer Research, 2012, 32, 4987-91.	1.1	10
138	Ductal adenocarcinoma of the prostate—reply. Human Pathology, 2011, 42, 606-607.	2.0	1
139	Tertiary Gleason pattern 5 on needle biopsy predicts greater tumour volume on radical prostatectomy. Pathology, 2011, 43, 693-696.	0.6	5
140	International Society of Urological Pathology Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Advances in Anatomic Pathology, 2011, 18, 301-305.	4.3	14
141	Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence. American Journal of Surgical Pathology, 2011, 35, 1134-1139.	3.7	93
142	Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens. Pathology, 2011, 43, 410-419.	0.6	9
143	International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Modern Pathology, 2011, 24, 6-15.	5.5	234
144	Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology, 2010, 42, 330-333.	0.6	14

3

145Genitourinary pathology in the new millennium. Pathology, 2010, 42, 317-318.0.4146Ductal adenocarcinoma of the prostate diagnosed on transurethral biopsy or resection is not always indicative of aggressive disease: implications for clinical management. BJU International, 2010, 105, 476-480.2.5147Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology, 2010, 42, 650-654.0.4148Gleason scoring: a comparison of classical and modified (International Society of Urological) Tj ETQq0 0 0 rgBT /Overlage	.6 (	
<ul> <li>indicative of aggressive disease: implications for clinical management. BJÚ International, 2010, 105, 476-480.</li> <li>Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 0.4 cases. Pathology, 2010, 42, 650-654.</li> <li>Gleason scoring: a comparison of classical and modified (International Society of Urological) Tj ETQq0 0 0 rgBT /Overlage.</li> </ul>		0
<ul> <li><sup>147</sup> cases. Pathology, 2010, 42, 650-654.</li> <li>Gleason scoring: a comparison of classical and modified (International Society of Urological) Tj ETQq0 0 0 rgBT /Overl.</li> </ul>	5 2	26
	.6 :	111
	lock 10	Tf 50 622 42
149Renal Cell Neoplasms of Oncocytosis Have Distinct Morphologic, Immunohistochemical, and Cytogenetic Profiles. American Journal of Surgical Pathology, 2010, 34, 620-626.3.7	7 {	58
Expression of PSA-RP2, an alternatively spliced variant from the PSA gene, is increased in prostate cancer tissues but the protein is not secreted from prostate cancer cells. Biological Chemistry, 2010, 391, 461-6.	5 8	8
Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2.5 2010, 19, 1755-1765.	5 :	13
Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Human Pathology, 2010, 41, 281-285.	0 0	63
<ul> <li>New Genomic Structure for Prostate Cancer Specific Gene PCA3 within BMCC1: Implications for</li> <li>Prostate Cancer Detection and Progression. PLoS ONE, 2009, 4, e4995.</li> </ul>	5 5	74
What is the molecular pathology of low-risk prostate cancer?. World Journal of Urology, 2008, 26, 431-436.	2 4	4
A novel transcript from the <i>KLKP1</i> gene is androgen regulated, downâ€regulated during prostate cancer progression and encodes the first nonâ€serine protease identified from the human kallikrein 2.3 gene locus. Prostate, 2008, 68, 381-399.	3 :	23
<ul> <li>Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate</li> <li>cancer. British Journal of Cancer, 2008, 99, 491-501.</li> </ul>	4 8	59
Tissue-specific promoter utilisation of the kallikrein-related peptidase 157 genes, <i>KLK5</i> and <i>KLK7</i> , and cellular localisation of the encoded proteins suggest roles in 2.5 exocrine pancreatic function. Biological Chemistry, 2008, 389, 99-109.	5 :	17
Loss of Heterozygosity at the <i>BRCA2</i> Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline <i>BRCA2</i> Mutation. 7.0 Clinical Cancer Research, 2008, 14, 2953-2961.	0 :	37
<ul> <li>Kallikrein-related Peptidase 4 (KLK4) Initiates Intracellular Signaling via Protease-activated Receptors</li> <li>(PARs). Journal of Biological Chemistry, 2008, 283, 12293-12304.</li> </ul>	4 :	122
Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biological 2.5 Chemistry, 2008, 389, 653-668.	5 5	38
161 Cellular angiofibroma of the scrotum. Pathology, 2008, 40, 330-333. 0.6	.6 (	6

162 Ductal adenocarcinoma of the prostate: current opinion and controversies. , 2008, 30, 237-46.

			_
#	ARTICLE	IF	CITATIONS
163	Prostatic ductal adenocarcinoma presenting as a urethral polyp: a clinicopathological study of eight cases of a lesion with the potential to be misdiagnosed as a benign prostatic urethral polyp. Pathology, 2007, 39, 476-481.	0.6	14
164	Significance of Minute Focus of Adenocarcinoma on Prostate Needle Biopsy. Urology, 2007, 70, 299-302.	1.0	9
165	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
166	17 DD3 expression in metastatic prostate cancer. BJU International, 2006, 97, 5-5.	2.5	0
167	7â€ <sup>-</sup> Positive margin rates in patients with a single positive core on extended TRUS biopsy. BJU International, 2006, 97, 2-2.	2.5	Ο
168	Atypical prostatic glandular proliferations on needle biopsy: Diagnostic implications, use of immunohistochemistry, and clinical significance. , 2006, 28, 104-10.		4
169	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 2005, 29, 1228-1242.	3.7	2,334
170	Use of multiple biomarkers for a molecular diagnosis of prostate cancer. International Journal of Cancer, 2005, 114, 950-956.	5.1	125
171	Significance of Stromal Reaction Patterns in Invasive Urothelial Carcinoma. American Journal of Clinical Pathology, 2005, 123, 851-857.	0.7	10
172	Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms. Endocrine-Related Cancer, 2005, 12, 875-889.	3.1	50
173	Significance of Stromal Reaction Patterns in Invasive Urothelial Carcinoma. American Journal of Clinical Pathology, 2005, 123, 851-857.	0.7	2
174	Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP. Clinical Cancer Research, 2004, 10, 314-323.	7.0	94
175	Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology, 2004, 45, 55-64.	2.9	167
176	Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology, 2002, 60, 315-319.	1.0	121
177	Expression analysis of ?-catenin and prostate-specific membrane antigen: Their potential as diagnostic markers for prostate cancer. International Journal of Cancer, 2002, 100, 228-237.	5.1	111
178	Phyllodes tumors of the breast: Correlation of nucleolar organizer regions with histopathological malignancy grading, flow cytometric DNA analysis and clinical outcome. Pathology International, 2001, 51, 866-873.	1.3	4
179	Atypical presentation of herpes simplex (chronic hypertrophic herpes) in a patient with HIV infection. Pathology, 2001, 33, 532-535.	0.6	41
180	Primary vaginal nonâ€Hodgkin's lymphoma after radiotherapy for Hodgkin's disease. Australian and New Zealand Journal of Medicine, 2000, 30, 404-405.	0.5	0

#	Article	IF	CITATIONS
181	Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues. Toxicological Sciences, 2000, 54, 19-29.	3.1	128
182	MOLECULAR DETECTION OF PROSTATE CELLS IN EJACULATE AND URETHRAL WASHINGS IN MEN WITH SUSPECTED PROSTATE CANCER. Journal of Urology, 1999, 161, 1337-1343.	0.4	32
183	GRADING OF RENAL CELL CARCINOMA. Urologic Clinics of North America, 1999, 26, 637-642.	1.8	27
184	Cervical Adenoid Basal Epitheliomas. American Journal of Surgical Pathology, 1999, 23, 1308.	3.7	2
185	EVALUATION OF MYECTOMIZED PARTIAL-THICKNESS ILEUM IN EXPERIMENTAL BLADDER AUGMENTATION. ANZ Journal of Surgery, 1998, 68, 587-591.	0.7	1
186	MESENTERIC PANNICULITIS: A MIMIC OF MALIGNANCY. ANZ Journal of Surgery, 1998, 68, 237-239.	0.7	17
187	Experimental pyeloureterectomy and calyceal neck transection with autotransplantation and bladder advancement. BJU International, 1998, 82, 877-881.	2.5	1
188	Non–rabies Lyssavirus human encephalitis from fruit bats: Australian bat Lyssavirus (pteropid) Tj ETQq0 0 0 rgB	T /Overloc 3.2	k 10 Tf 50 4 82
189	Metastatic Foamy Gland Carcinoma of the Prostate: A Potential Diagnostic Pitfall. Journal of Urologic Pathology, 1998, 9, 155-162.	0.3	1
190	Re: Malignant Cytological Washings From Radical Prostatectomy Specimens. Journal of Urology, 1997, 158, 889-889.	0.4	1
191	A new lyssavirus — fhe first endemic rabies-related virus recognized in Australia. Bulletin De L'Institut Pasteur, 1997, 95, 209-218.	0.6	94
192	Intussuscepted Partial-Thickness Ileal Valve in Continent Urinary Diversion. European Urology, 1997, 31, 102-107.	1.9	5
193	Primary lymphoma of pituitary gland: A neoplasm of acquired malt?. Endocrine Pathology, 1997, 8, 335-341.	9.0	17
194	Distribution Pattern of Basal Cells Detected by Cytokeratin 34 Beta E12 in Primary Prostatic Duct Adenocarcinoma. American Journal of Surgical Pathology, 1997, 21, 435-440.	3.7	44
195	Intravascular fasclitis: A case report and review of the literature. Pathology, 1996, 28, 8-11.	0.6	21
196	NODULAR FASCIITIS AND RELATED PSEUDOSARCOMATOUS LESIONS OF SOFT TISSUES. ANZ Journal of Surgery, 1996, 66, 22-25.	0.7	26
197	Abnormal prostatic cells in ejaculates from men with prostatic cancer - a preliminary report. BJU International, 1996, 78, 414-418.	2.5	33
198	Mango dermatitis: Allergic contact dermatitis to Mangifera indica. Australasian Journal of Dermatology, 1996, 37, 59-60.	0.7	32

#	Article	IF	CITATIONS
199	Prostatic carcinoma metastatizing to the testis — an unusual pattern of spread. British Journal of Urology, 1995, 75, 803-804.	0.1	8
200	Prostate-specific Antigen (PSA) and Cancer-Associated Serum Antigen (CASA) in Distinguishing Benign and Malignant Prostate Disease. International Journal of Biological Markers, 1995, 10, 221-225.	1.8	4
201	Mucin expression by transitional cell carcinomas of the bladder. British Journal of Urology, 1994, 73, 256-262.	0.1	55
202	Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progression. British Journal of Urology, 1994, 73, 526-532.	0.1	70
203	Squamous Cell Carcinoma In Situ Involving Mesonephric Remnants A Potential Diagnostic Pitfall. American Journal of Surgical Pathology, 1994, 18, 1265-1269.	3.7	6
204	Cerebral Metastasis of an Atrial Myxoma Mimicking an Epithelioid Hemangioendothelioma. American Journal of Surgical Pathology, 1994, 18, 107-111.	3.7	34
205	Mucin inclusions in urothelial carcinomas. Human Pathology, 1993, 24, 929-930.	2.0	0
206	Human papillomavirus DNA in glandular lesions of the uterine cervix Journal of Clinical Pathology, 1993, 46, 718-721.	2.0	8
207	Lymph Node Pseudotumor. American Journal of Surgical Pathology, 1993, 17, 91-92.	3.7	10
208	Absence of human papillomavirus in cervical adenocarcinoma Journal of Clinical Pathology, 1992, 45, 271-272.	2.0	0
209	An immunohistological demonstration of c-erbB-2 oncoprotein expression in primary urothelial bladder cancer. Urological Research, 1992, 20, 117-120.	1.5	23
210	VALUE OF FINE NEEDLE ASPIRATION BIOPSY CYTOLOGY IN THE DIAGNOSIS OF DISCRETE HEPATIC LESIONS SUSPICIOUS FOR MALIGNANCY. ANZ Journal of Surgery, 1992, 62, 540-544.	0.7	24
211	Squamous cell carcinoma arising in a case of vulvitis granulomatosa or vulval variant of Melkersson-Rosenthal syndrome. Gynecologic Oncology, 1991, 41, 263-269.	1.4	6
212	A Clinicopathological Study of Adenocarcinoma in Situ of the Cervix. The Influence of Cervical HPV Infection and Other Factors, and the Role of Conservative Surgery. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1991, 31, 179-183.	1.0	53
213	Evaluation of a Bladder Advancement Extension Graft Technique. British Journal of Urology, 1990, 66, 606-612.	0.1	1
214	Application of the Invaginated Sleeve Technique to Form a Continent Ileal Urostomy. British Journal of Urology, 1990, 65, 457-461.	0.1	2
215	Development of the Invaginated Sleeve Technique for Continent Cystostomies in Dogs. British Journal of Urology, 1989, 63, 276-280.	0.1	8
216	A Case of Rabies. BMJ: British Medical Journal, 1965, 1, 1596-1596.	2.3	5

#	Article	IF	CITATIONS
217	Intraductal Carcinoma of the Prostate and Nuclear Size. American Journal of Surgical Pathology, 0, Publish Ahead of Print, .	3.7	Ο